Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Fifty Day Moving Average - What's Next?

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $12.58 and traded as low as $8.92. Seres Therapeutics shares last traded at $9.70, with a volume of 130,941 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MCRB shares. StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 1st. The Goldman Sachs Group lowered their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research note on Friday, March 14th. Finally, Chardan Capital restated a "buy" rating and set a $25.00 price objective on shares of Seres Therapeutics in a research report on Thursday, March 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $80.00.

Seres Therapeutics Stock Performance

The business has a 50 day simple moving average of $12.10 and a 200-day simple moving average of $14.83. The firm has a market capitalization of $77.07 million, a price-to-earnings ratio of -38.43 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($2.21). Equities analysts predict that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock valued at $1,314,000 after buying an additional 255,014 shares in the last quarter. Virtu Financial LLC increased its stake in Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 18,191 shares during the period. Vontobel Holding Ltd. boosted its stake in shares of Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company's stock valued at $780,000 after purchasing an additional 543,469 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Seres Therapeutics by 15.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock valued at $720,000 after purchasing an additional 117,107 shares in the last quarter. Finally, Avantax Advisory Services Inc. increased its stake in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after buying an additional 28,500 shares during the period. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.